Skip to main content
main-content

01.12.2016 | Retraction Note | Ausgabe 1/2016 Open Access

Cancer Cell International 1/2016

Retraction Note: Psoriasin (S100A7) is a novel biomarker for lung squamous cell carcinoma in humans

Zeitschrift:
Cancer Cell International > Ausgabe 1/2016
Autoren:
Guijuan Liu, Qiang Wu, Guilan Liu, Xueying Song, Jihong Zhang
Wichtige Hinweise
The online version of the original article can be found under doi:10.​1186/​s12935-014-0154-0.
The online version of the original article can be found at http://​dx.​doi.​org/​10.​1186/​s12935-014-0154-0.

Retraction to: Cancer Cell International (2015) 15:18 DOI 10.1186/s12935-014-0154-0

The editors are retracting this article [ 1] as it has been previously published in the International Journal of Clinical and Experimental Pathology [ 2] and it is therefore a redundant publication. The authors could not be reached by the journal for comment on the retraction.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2016

Cancer Cell International 1/2016 Zur Ausgabe

Neu im Fachgebiet Onkologie

07.05.2021 | DDG-Tagung 2021 | Kongressbericht | Nachrichten

Prävention von aktinischen Keratosen intensivieren

07.05.2021 | DDG-Tagung 2021 | Kongressbericht | Nachrichten

Von Wirkung und Nebenwirkung

07.05.2021 | DDG-Tagung 2021 | Kongressbericht | Nachrichten

Progredienzangst frühzeitig erkennen

07.05.2021 | DDG-Tagung 2021 | Kongressbericht | Nachrichten

Schleimhautmelanom: Neue Therapieoption in Sicht?

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise